858 results on '"Stüve, Olaf"'
Search Results
52. Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis
53. Cytokine levels in CSF and neuropsychological performance in HIV patients
54. DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation
55. The effects of natalizumab on the innate and adaptive immune system in the central nervous system
56. Prion proteins: Physiological functions and role in neurological disorders
57. Multiple Sclerosis in the Elderly Patient
58. Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?
59. Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis: In Search of Biomarkers
60. Optic neuritis presenting with amaurosis fugax
61. MULTIPLE SCLEROSIS: Natalizumab to fingolimod—the washout whitewash
62. Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array
63. Multiple Sclerosis Disease Progression and Paradichlorobenzene: A Tale of Mothballs and Toilet Cleaner
64. Factors that influence adherence with disease-modifying therapy in MS
65. α4-Integrin antagonism with natalizumab: Effects and adverse effects
66. Immunomodulatory treatment strategies in multiple sclerosis
67. Immunosuppression in clinical practice: Approaches to individualized therapy
68. Pharmacological Treatment of Early Multiple Sclerosis
69. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations
70. Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects
71. Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’
72. Evaluation of HMG-CoA Reductase Inhibitors for Multiple Sclerosis: Opportunities and Obstacles
73. CD11c+CD88+CD317+myeloid cells are critical mediators of persistent CNS autoimmunity
74. Systems Approaches to Unravel T Cell Function and Therapeutic Potential in Autoimmune Disease
75. Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
76. Statins as potential therapeutic agents in multiple sclerosis
77. Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica: Implication for Cellular Immune Responses
78. Cerebral and Cervical Venous Outflow Abnormalities Are Dynamic
79. Human Aquaporin 4281-300 Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03: 01: Relevance for Diagnosing and Monitoring Patients With Neuromyelitis Optica
80. MULTIPLE SCLEROSIS: Combination therapy in MS—still a valid strategy
81. No Cerebral or Cervical Venous Insufficiency in US Veterans With Multiple Sclerosis
82. Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis
83. A critical appraisal of treatment decisions in multiple sclerosis—old versus new
84. No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis
85. Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles, Pathophysiology and Therapeutic Choices
86. Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
87. Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes
88. CD11c+CD88+CD317+myeloid cells are critical mediators of persistent CNS autoimmunity
89. The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?
90. Translational Research in Neurology and Neuroscience 2010: Multiple Sclerosis
91. Reversible Alopecia Associated With Glatiramer Acetate
92. Natalizumab and Progressive Multifocal Leukoencephalopathy: What Are the Causal Factors and Can It Be Avoided?
93. Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling
94. DNA β-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
95. Immunotherapy for Multiple Sclerosis: The Curious Case of Interferon Beta
96. Depletion of B Lymphocytes From Cerebral Perivascular Spaces by Rituximab
97. A 69-YEAR-OLD MAN WITH LEFT HEMISPHERIC NECROTIZING MASS LESION
98. Is 1+1 0, 1, 2, or 11? Arithmetics of antiinflammatory agents in autoimmunity
99. 200 Years After Darwin
100. Genetic Polymorphism at Codon 129 of the Prion Protein Gene Is Not Associated With Multiple Sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.